• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

New Data on Investigational Tralokinumab for Treatment of AD

Video

In this exclusive video interview with Dermatology Times®, Andrew Blauvelt, MD, MBA, discusses the newest phase 3 clinical data on investigational tralokinumab as a potential treatment option in atopic dermatitis.

In this exclusive video interview with Dermatology Times®, Andrew Blauvelt, MD, MBA, a dermatologist and president of Oregon Medical Research Center in Portland, Oregon, discusses the newest phase 3 clinical data on tralokinumab (LEO Pharma).

Tralokinumab is an investigational monoclonal antibody that specifically neutralizes interleukin (IL)-13, a key driver of atopic dermatitis (AD) and is currently being evaluated by the FDA. Hear what he has to say about the newest data from the ECZTEND (NCT03587805) trial in the video below.

Related Videos
Video 2 - "Atopic Dermatitis and Contact Dermatitis: Navigating Intersecting Pathways and Optimal Management Strategies"
Video 1 - "Decoding Atypical Atopic Dermatitis: Unraveling Complex Cases and Advanced Diagnostic Strategies"
Elizabeth Kiracofe, MD, an expert on atopic dermatitis
© 2024 MJH Life Sciences

All rights reserved.